Flowable Hemostats Market Forecast and Outlook By Fact.MR
- The flowable hemostats market is estimated at USD 1.4 billion in 2025.
- Based on Fact.MR analysis, the market is projected to reach USD 1.5 billion in 2026 and USD 3.1 billion by 2036.
- Fact.MR projects the market to expand at 7.5% CAGR during the forecast period.
| Metric |
Value |
| Estimated Value in 2026 |
USD 1.5 billion |
| Forecast Value in 2036 |
USD 3.1 billion |
| Forecast CAGR (2026 to 2036) |
7.5% |
Summary of Flowable Hemostats Market
- Demand Drivers
- Increasing Surgical Volumes: Rising elective and emergency surgeries are increasing demand for flowable hemostats across general surgery and cardiovascular procedures. Hospitals are adopting approved bleeding control products to reduce operative complications and shorten procedure duration.
- Transition Toward Combination Hemostats: Hospitals increasingly prefer combination flowable hemostats containing thrombin components due to faster clot formation and improved surgical efficiency. Demand is strongest in high-blood-loss procedures requiring rapid bleeding management.
- Asia Pacific Healthcare Expansion: Public and private hospital expansion across China and Southeast Asia is improving access to biologic surgical hemostatic products. Growth is supported by rising healthcare investment and wider adoption of minimally invasive surgery.
- Key Segments Analyzed
- By Material: Bovine gelatin accounts for nearly 63% share in 2026 due to strong absorption capacity and broad surgical compatibility.
- By Product: Combination hemostats hold around 46% share in 2026 supported by faster clotting performance during complex surgeries.
- By Application: General surgery accounts for nearly 34% share in 2026 due to high procedural volume across hospitals globally.
- By End User: Hospitals and clinics hold close to 71% share in 2026 supported by high surgical admissions and emergency care infrastructure.
- By Distribution Channel: Direct tender sales account for nearly 58% share in 2026 due to long-term hospital supply agreements and centralized purchasing systems.
- By Geography: China records the fastest CAGR at 8.4% through 2036 supported by rising elective surgeries and hospital adoption of biologic hemostatic agents.
- Analyst Opinion at Fact.MR
- Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, ' Hospital formulary boards at high-volume surgical centers are increasingly standardizing combination flowable hemostats to reduce operative time and lower complication risk. This shift is reshaping supply agreements and supplier positioning across major surgical markets.’
- Strategic Implications
- Manufacturers should expand combination hemostat portfolios supported by clinical outcome data for hospital formulary committees in the United States and Germany. Strong clinical evidence improves formulary inclusion and long-term supply agreements.
- Companies with direct tender relationships should increase surgical training and clinical education programs across public hospitals in China. This strategy supports adoption in the growing national market.
- Third-party distributors in Brazil and Japan should strengthen product training and regulatory support capabilities. Better local support can improve hospital penetration across underserved surgical specialties.
- The market is projected to generate nearly USD 1.6 billion in additional revenue between 2026 and 2036. Growth is supported by rising global surgical procedure volumes and increasing hospital preference for combination flowable hemostats that improve intraoperative bleeding control. Adoption remains constrained in price-sensitive healthcare systems and public-sector hospitals across emerging economies.
- Growth is led by China with an estimated CAGR of 8.4% through 2036. Demand is driven by expanding elective surgery volumes and healthcare modernization investment. The United States is projected to grow at 7.0% CAGR supported by high surgical throughput and broad access to branded hemostatic agents. Germany is forecast at 6.7% CAGR as hospital reimbursement systems increasingly favor faster surgical bleeding management technologies. Japan is estimated to expand at 6.3% CAGR due to rising surgical demand from the aging population and purchase of approved biologic hemostats. Brazil is projected to grow at 6.0% CAGR supported by private hospital expansion and increasing adoption across cardiovascular and orthopedic surgeries.
Segmental Analysis
Flowable Hemostats Market Analysis by Material
Bovine gelatin-based flowable hemostats account for nearly 63% share in 2026 due to strong absorption capacity and broad surgical compatibility. Demand remains concentrated across general surgery and cardiovascular procedures. Baxter International Inc. launched Floseal + Recothrom, an active flowable hemostat with recombinant thrombin, for surgical bleeding control. [1] The launch supports demand for flowable hemostats with faster preparation and thrombin-based clotting performance.
- Bovine Gelatin Dominance: Hospitals continue preferring bovine gelatin products due to established clinical performance and compatibility with thrombin-based formulations.
- Porcine Gelatin Adoption: Porcine gelatin products are gaining traction across selected European and Asia Pacific markets with fewer regulatory or dietary restrictions.
- Stable Raw Material Supply: Established biologic sourcing networks support stable gelatin availability for large-scale hemostatic product manufacturing.
Flowable Hemostats Market Analysis by Product
Combination hemostats hold around 46% share in 2026 due to faster clot formation during complex surgical procedures. Demand is increasing in high-bleeding-risk surgeries where rapid hemostasis is clinically important.
- Combination Product Growth: Surgeons increasingly prefer thrombin-integrated flowable hemostats due to faster bleeding control and shorter operative time.
- Active Hemostat Expansion: Active hemostats are gaining adoption in neurosurgical and spinal procedures requiring precise tissue interaction.
- Passive Hemostat Stability: Passive products maintain demand across cost-sensitive hospitals and routine surgical procedures.
Flowable Hemostats Market Analysis by Application
General surgery accounts for nearly 34% share in 2026 due to high procedural volume across hospitals globally. Flowable hemostats are increasingly incorporated into routine surgical workflows. Johnson & Johnson MedTech product literature identifies SURGIFLO as a flowable gelatin hemostatic matrix prepared with thrombin for surgical bleeding control. [2]The product evidence supports demand for gelatin-based flowable matrices in general, orthopedic, and spine procedures.
- General Surgery Leadership: Abdominal and laparoscopic procedures continue generating the leading application demand for flowable hemostatic agents.
- Cardiac Surgery Demand: Cardiovascular procedures are increasing usage of thrombin-based flowable hemostats due to higher bleeding management complexity.
- Orthopedic and Neuro Expansion: Orthopedic and neuro-spine procedures are using more flowable hemostats in minimally invasive surgeries.
Flowable Hemostats Market Analysis by End User
Hospitals and clinics hold close to 71% share in 2026 supported by high surgical admission volume and emergency care infrastructure. Large healthcare systems account for the majority of institutional product demand. Johnson & Johnson MedTech lists SURGIFLO with thrombin as a hemostatic matrix used for mild oozing, moderate flowing blood, and stronger bleeding control needs. [3]The product fit supports hospital demand for active flowable hemostats in surgical departments.
- Hospital Dominance: Multi-specialty hospitals remain the leading consumers of flowable hemostats due to consistent surgical throughput.
- ASC Adoption Growth: Ambulatory surgery centers are increasing hemostat usage across outpatient orthopedic and general surgery procedures.
Flowable Hemostats Market Analysis by Distribution Channel
Direct tender sales account for nearly 58% share in 2026 supported by long-term hospital supply agreements and centralized purchase systems. Baxter reported the U.S. launch of PERCLOT and its earlier launch of Floseal + Recothrom in its surgical hemostat portfolio. [4] The update supports broader hospital access to passive and active hemostat options.
- Direct Tender Preference: Hospital systems increasingly prefer contracted purchasing agreements with clinical support commitments from manufacturers.
- Distributor Network Role: Third-party distributors remain important across smaller hospitals and emerging regional healthcare systems.
- Digital Sourcing Expansion: Online medical sourcing platforms are improving product sourcing efficiency for ambulatory and smaller clinical facilities.
Drivers, Restraints, and Opportunities
The flowable hemostats market is expanding from surgical specialty usage toward broader standard-of-care adoption across high-volume hospitals. Demand growth is supported by rising surgical complexity and increasing preference for faster intraoperative bleeding control technologies. Baxter showcased Floseal + Recothrom as a commercial flowable hemostat addition to its surgical portfolio. [5] The portfolio update supports hospital access to active flowable hemostats in surgical care settings.
- EU MDR Compliance Pressure: Updated European medical device regulations are increasing documentation requirements for surgical hemostatic products.
- Asia Pacific Surgical Expansion: Government-funded hospital infrastructure investment across China, India, and Southeast Asia is expanding institutional demand for flowable hemostats.
- Combination Hemostat Premiumization: Clinical evidence supporting lower blood loss and shorter operative time is strengthening hospital preference for combination hemostatic products.
Regional Analysis
The flowable hemostats market is assessed across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, covering 40+ country-level demand by product type, application, end user, and distribution channel. The full report offers market attractiveness analysis by region and country.
.webp "Top Country Growth Comparison Flowable Hemostats Market Cagr (2026 2036)")
| Country |
CAGR (2026 to 2036) |
| China |
8.4% |
| United States |
7.0% |
| Germany |
6.7% |
| Japan |
6.3% |
| Brazil |
6.0% |
Source: Fact.MR analysis based on forecasting model and primary research
Asia Pacific Flowable Hemostats Market Analysis
Rising surgical procedure volumes and public hospital infrastructure investment are strengthening flowable hemostat demand across Asia Pacific. China's healthcare modernization initiatives and Japan's aging-driven surgical load are creating differentiated demand profiles across the region.
- China: Demand in China is forecast to rise at 8.4% CAGR through 2036. Growth is supported by tertiary hospital expansion and rising elective surgery volumes under national healthcare modernization programs. Public hospitals are increasing purchase of biologic hemostats across cardiovascular and general surgery departments. International manufacturers are strengthening regional distribution and surgeon training programs.
- Japan: Japan is expected to register 6.3% CAGR till 2036. Demand is driven by aging population surgery volumes across orthopedic and cardiac procedures. Public reimbursement support for biologic hemostats is improving adoption across major hospital systems. Demand remains concentrated in clinically validated and premium surgical products.
North America Flowable Hemostats Market Analysis
The United States accounts for the leading national demand for flowable hemostats, supported by high surgical volume, GPO-negotiated formulary access, and established clinical preference for combination hemostatic agents. Branded product manufacturers maintain strong hospital relationships through direct clinical education and supply contracts.
- United States: The United States market is estimated to expand at 7.0% CAGR by 2036. Demand is supported by high-volume cardiovascular and orthopedic surgeries along with broad formulary access for branded hemostatic agents. Manufacturers strengthen GPO supply contracts and clinical support programs across hospital networks.
Europe Flowable Hemostats Market Analysis
EU MDR compliance requirements and DRG-based hospital reimbursement frameworks affect flowable hemostat adoption across European markets. Germany leads European demand due to its high per-capita surgical volume and strong formulary standardization across university hospital networks.
- Germany: Germany is forecast to grow at 6.7% CAGR by 2036. Demand is supported by high surgical throughput and standardized purchase across university hospitals. Combination hemostats are gaining wider adoption due to improved intraoperative bleeding management and reduced procedure time.
Latin America Flowable Hemostats Market Analysis
Private hospital expansion and rising surgical procedure volumes across Brazil and Colombia are increasing institutional demand for flowable hemostatic products. Import-dependent markets face pricing pressure from currency fluctuation and local regulatory approval timelines.
- Brazil: Brazil is anticipated to expand at 6.0% CAGR through 2036. Growth is driven by rising private hospital investment and increasing use of bleeding management protocols across cardiovascular and orthopedic procedures. Regulatory approvals for biologic hemostatic products are also improving institutional product access.
Company Positioning for Market Players
- The flowable hemostats market is becoming increasingly competitive around clinical performance and hospital formulary positioning. Manufacturers with strong surgical outcome data are improving access across high-volume hospital systems. Product differentiation is centered on faster clot formation and lower intraoperative bleeding risk.
- Combination hemostats are gaining stronger adoption across cardiovascular and orthopedic procedures where operating room efficiency affects hospital reimbursement performance. Companies with thrombin-integrated portfolios maintain stronger pricing power across developed healthcare markets. Passive hemostats serve cost-sensitive hospitals and routine surgical procedures.
- Direct hospital relationships remain important for company positioning. Large manufacturers are expanding surgeon training and clinical education programs to improve product standardization across operating rooms. GPO agreements and long-term tender contracts influence institutional purchasing decisions across North America and Europe. Regulatory compliance capability is becoming more important across European markets following MDR implementation. Manufacturers with updated clinical documentation and post-market surveillance systems maintain stronger access to hospital tender frameworks. Regional distributors across Latin America and Asia Pacific are increasing investment in regulatory support and surgical training infrastructure. Supplier positioning increasingly depends on clinical validation and stable biologic raw material sourcing capability.
Key Players
- Johnson & Johnson MedTech
- Baxter International Inc.
- Teleflex Incorporated
- B. Braun SE
- Integra LifeSciences
- Pfizer Inc.
Bibliography
- Baxter International Inc. (2023). Baxter showcases Floseal + Recothrom flowable hemostat at AORN [Press release].
- Johnson & Johnson MedTech. (2025). SURGIFLO Hemostatic Matrix product information.
- Johnson & Johnson MedTech. (2025). SURGIFLO Hemostatic Matrix with thrombin product information.
- Baxter International Inc. (2024). Fourth-quarter and full-year 2023 results press release.
- Baxter International Inc. (2023). Baxter showcases surgical portfolio innovations at AORN.
This Report Addresses
- Analysis of flowable hemostat demand across product type, application, end user, and distribution channel with 2026 share benchmarks.
- Market forecast from USD 1.5 billion in 2026 to USD 3.1 billion by 2036 at 7.5% CAGR with opportunity assessment across combination and active hemostat segments.
- Growth analysis across China, the United States, and Germany linked with surgical volume expansion and hospital formulary adoption.
- Segment analysis across material type and product categories with regional demand forecasts and distribution channel breakdowns.
- Competitive analysis of Johnson & Johnson, Baxter International, Integra LifeSciences, B. Braun SE, and other leading manufacturers.
- Regulatory analysis covering EU MDR 2017/745 compliance requirements and national reimbursement policy updates affecting hemostatic product adoption.
- Report available with surgical procedure volume data and hospital purchase analysis.
Flowable Hemostats Market Definition
The flowable hemostats market covers biologic and synthetic hemostatic agents in flowable or paste form used during surgical procedures to achieve rapid bleeding control at wound sites. Products are applied to bleeding surfaces across general, cardiac, orthopedic, and neurosurgical procedures.
Flowable Hemostats Market Inclusions
The study covers global and regional forecasts from 2026 to 2036 by material type, product type, application, end user, and distribution channel. It includes bovine and porcine gelatin-based flowable hemostats, combination hemostats with active thrombin components, passive hemostats, and active hemostats across hospital and ambulatory surgery center distribution channels.
Flowable Hemostats Market Exclusions
The study excludes absorbable hemostatic sponges, oxidized cellulose sheets, and fibrin sealants supplied in spray or patch format. It omits topical wound care products used outside surgical settings and hemostatic dressings intended for trauma field applications. Standalone thrombin solutions not formulated as flowable agents are outside the defined scope.
Flowable Hemostats Market Research Methodology
- Primary Research
- Interviews with hospital supply directors, surgical supply chain managers, operating room nurses, general surgeons, and cardiac and orthopedic surgery department heads across the United States, Germany, China, Japan, and Brazil.
- Desk Research
- Analysis of Johnson & Johnson, Baxter International, and Integra LifeSciences public filings and press releases, FDA 510(k) clearance databases, and surgical product formulary adoption reports from hospital group purchasing organizations covering 2024 and 2025 updates.
- Market-Sizing and Forecasting
- Hybrid model using top-down surgical procedure volume data from national health ministries combined with bottom-up channel volume estimates from hospital purchasing data and distributor interview records. Forecasts are developed separately by product type and application.
- Data Validation and Update Cycle
- Outputs are validated through hospital formulary approval records, Group Purchasing Organization contract disclosures, and surgical product sales data from manufacturer earnings reports. Updated with annual surgical procedure volume data from national health agencies.
